ClinicalTrials.gg
Enrolling by invitationNCT07063381LESCAFUpdated May 8, 2026

Low-frequency Electrical Stimulation for Cognitive Enhancement in Atrial Fibrillation

An interventional study of tVNS in Cognitive Function Abnormal and Atrial Fibrillation (AF), sponsored by Bakulev Scientific Center of Cardiovascular Surgery. Enrolling by invitation at 2 sites in Russia. Open to participants aged 60 Years to 90 Years. Per ClinicalTrials.gov, last updated 2026-05-08.

Sponsored by Bakulev Scientific Center of Cardiovascular Surgery · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
60 Years to 90 Years
Sex
All
01

Study summary

Cognitive function in patients with atrial fibrillation (AF) is often impaired due to the complex influence of various factors (cerebral hypoperfusion, neurodegeneration, microemboli, hypertension, chronic inflammation). This leads to impairment of cognitive functions, including attention, memory, executive functions, and speed of information processing. The search for affordable and safe methods to maintain or improve cognitive function in this group of people is an urgent task of modern medicine. One of the promising approaches is percutaneous low-frequency electrical stimulation of the auricular branch of the vagus nerve (transcutaneous Vagus Nerve Stimulation - tVNS).

The auricular (auricular) branch of the vagus nerve is a peripheral branch of the vagus nerve innervating the skin of the auricle in the area of the tragus and the inner part of the external auditory canal. The tVNS engages the sensory fibres of the vagus nerve and thus mimics the sensory input to the brainstem, forming the so-called auriculo-vagal afferent pathway. Since these fibres project directly to the nucleus of the solitary pathway (solitary tract), which, in turn, has direct and indirect projections to the nuclei providing noradrenergic, endorphinergic and serotoninergic fibres in various parts of the brain regulating systemic indices of cardiovascular, respiratory and immunological functions, the organism's response to stimulation of the auricular branch of the vagus nerve is systemic in nature.

Stimulation of this nerve can modulate central nervous system (CNS) activity, affecting processes related to memory, attention and emotional state. Mechanisms of action of tVNS include modulation of parasympathetic activity, enhancement of neuroplasticity through increased expression of neurotrophic factors (e.g., BDNF), improvement of cerebral blood circulation, and regulation of neuroinflammation (reduction of proinflammatory cytokines).

02

Conditions studied

  • Cognitive Function Abnormal
  • Atrial Fibrillation (AF)

Keywords

  • transcutaneous vagus nerve stimulation
  • vagus nerve stimulation
  • atrial fibrillation
  • auricular vagus nerve stimulation
  • cognitive functions
  • memory
  • executive functions
  • information processing speed
  • modulation of parasympathetic activity
  • neuroplasticity
  • neurotrophic factors
  • cerebral blood flow
  • inflammatory cytokines
03

In context

Cognition Disorders

399 studies on the registry are indexed under Cognition Disorders; 72 are open to participants now.

This study's planned enrollment of 60 is close to the median of 66 across 272 interventional studies indexed under Cognition Disorders.

Browse Cognition Disorders studies →

Lead sponsor

Bakulev Scientific Center of Cardiovascular Surgery is the lead sponsor of 8 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
60 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age over 60 years,
  • Permanent form of AF,
  • Severe and mild cognitive impairment (\<26 points on the -8 test),
  • The possibility of regular repeat visits for 6 months.

Exclusion criteria

Exclusion Criteria:

  • Atrioventricular blockade of 2-3 degree,
  • Expressed sinus bradycardia with resting heart rate \< 40 bpm
  • Any oncological diseases,
  • Severe chronic liver and kidney pathology,
  • Chronic viral infections.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
60 participants (estimated)

Study arms

  • Active comparator
    Active tVNS

    Active stimulation will be carried out using the tVNS device with an ear clip attached to the tragus of the left ear at a frequency of 20 Hz, 250 μs at a current slightly below the discomfort threshold. The device's operating mode is active therapeutic.

    Device: tVNS

  • Sham comparator
    Sham tVNS

    Fictitious stimulation will be carried out using the tVNS device with an ear clip attached to the tragus of the left ear at a frequency of 20 Hz, 250 μs at a current slightly below the discomfort threshold. The device's operating mode is research mode.

    Device: tVNS

Interventions

  • DevicetVNS

    tVNS will be performed daily after workouts for 60 minutes over a period of 6 months.

06

What researchers measure

Primary outcomes

  1. Dynamics of neural activity of the brain.

    Changes in the characteristics of time-frequency analysis of the neural activity of the brain associated with the performance of a cognitive task.

    Time frame: This parameter will be assessed at the beginning of the study (initially) and at the end of the study (6 months) in the active and fictitious stimulation groups.

Secondary outcomes

  1. Reaction Time (RT) Changes & EEG Correlates

    Changes in reaction time (RT) during the perception and classification of ambiguous visual stimuli (Necker cubes) by a patient. The test is conducted with simultaneous EEG recording during the visual task (determining the orientation of the Necker cube - right-oriented or left-oriented configuration). The presentation of ambiguous stimuli, such as the Necker cube, leads to an increase in reaction time due to the need to resolve perceptual conflict and make decisions under uncertainty. Parallel EEG recording reveals specific neural correlates of this process (N200 - conflict, P300 - decision/classification, frontal theta - cognitive control, gamma - perceptual reorganization), which are directly related to the observed changes in reaction speed. Analysis of these EEG markers together with RT provides deep insight into brain dynamics during the processing of ambiguous information.

    Time frame: This parameter will be assessed at the beginning of the study (initially) and at the end of the study (6 months) in the active and fictitious stimulation groups.

  2. Attention Level Changes & Error Rates

    Changes in the level of attention during the perception and classification of ambiguous visual stimuli (Necker cubes) by a patient. The test is conducted with simultaneous EEG recording during the visual task (determining the orientation of the Necker cube - right-oriented or left-oriented configuration). The frequency of actual errors (incorrect reporting) is assessed. The presentation of ambiguous stimuli, such as the Necker cube, requires an increased level of attention (especially executive control), reflected in specific EEG patterns (theta, N2, P3). The primary sources of errors are perceptual instability (switches during response) and unresolved conflict/uncertainty. Analysis of EEG (ERN/Pe) allows studying the process of error detection and correction itself.

    Time frame: This parameter will be assessed at the beginning of the study (initially) and at the end of the study (6 months) in the active and fictitious stimulation groups.

  3. Dynamics of the cognitive test MoCA-8 (Montreal Cognitive Assessment).

    Changes in the MoCA-8 score. Scores on the MoCA-8 test range from 0 to 30, where a score \<26 may indicate cognitive impairment.

    Time frame: This parameter will be assessed at the beginning of the study (initially) and at the end of the study (6 months) in the active and fictitious stimulation groups.

07

Study locations

2 sites
  • Bakulev National Medical Research Center for Cardiovascular Surgery
    Moscow, 121552, Russia
  • Neurodynamics and Cognitive Technologies Research Laboratory of the Neuroscience Research Institute
    Nizhny Novgorod, Russia
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2025 (actual). Primary completion is estimated for Sep 2027, 23 months after the start.

Of 88 non-industry interventional studies with no phase under Cognition Disorders, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 55. This study's planned 23 months is below that.

Counting every sponsor, half of 93 studies reached it within 34 months; a quarter within 16 and three quarters within 55.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 23, 2025
First posted
Jul 14, 2025
StartActual
Sep 9, 2025
Primary completionEst.
Sep 1, 2027
CompletionEst.
Dec 31, 2027
Last update
May 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07063381
Lead sponsor
Bakulev Scientific Center of Cardiovascular Surgery
Collaborators
Lobachevsky University
Responsible party
Vladimir A Shvartz, MD (Principal Investigator, Bakulev Scientific Center of Cardiovascular Surgery) — Principal investigator
First posted
Jul 14, 2025
Start date
Sep 9, 2025
Primary completion
Sep 1, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
May 8, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion